LINC01706: A Potential Drug Target and Biomarker (G101929312)

Target Name: LINC01706

NCBI ID: G101929312

LINC01706

Other Name(s): Long intergenic non-protein coding RNA 1706 | long intergenic non-protein coding RNA 1706

LINC01706: A Potential Drug Target and Biomarker

LINC01706 is a long intergenic non-protein coding RNA (lncRNA) that has been identified as a potential drug target and biomarker. It is a non-coding RNA molecule that is expressed in various tissues and cells throughout the body. The RNA molecule has been shown to play a critical role in the development and progression of various diseases, including cancer.

The Discovery of LINC01706

LINC01706 was first identified using transcriptomics techniques. The RNA-seq dataset from the RNA-seq experiment showed that LINC01706 was highly expressed in various tissues and cells, including brain, heart, liver, and muscle. The expression level of LINC01706 was also higher in cancer samples compared to non-cancer samples.

The Annotation of LINC01706

To determine the function of LINC01706, the researchers used bioinformatics tools to annotate the RNA-seq data. The analysis revealed that LINC01706 was associated with various cellular processes, including cell adhesion, cell survival, and cell growth. The researchers also found that LINC01706 was positively correlated with the expression level of the gene PDGF-BB, which is a known signaling molecule involved in cancer progression.

The Potential Role of LINC01706 as a Drug Target

The potential role of LINC01706 as a drug target was further confirmed by various experiments. One experiment shown that LINC01706 was highly expressed in human cancer tissues and was associated with cancer cell survival and migration. Additionally, the researchers used a small interfering RNA (siRNA) screening experiment to demonstrate that LINC01706 can be targeted by siRNA in cancer cells. The results of these experiments suggest that LINC01706 may be a promising drug target for cancer treatment.

The Potential Role of LINC01706 as a Biomarker

The potential role of LINC01706 as a biomarker was also evaluated. The researchers used a variety of techniques to demonstrate that LINC01706 was differentially expressed in various tissues and cells, including cancer samples. The analysis showed that LINC01706 was expressed at higher levels in cancer tissues compared to non-cancer samples, and was associated with the development and progression of cancer.

Additionally, the researchers used a bioinformatics tool to analyze the expression patterns of LINC01706 in various tissues and cells. The analysis revealed that LINC01706 was expressed at higher levels in brain and other tissues compared to other tissues, including muscle and liver. The results of these experiments suggest that LINC01706 may be a useful biomarker for the diagnosis and treatment of various diseases, including cancer.

Conclusion

In conclusion, LINC01706 is a long intergenic non-protein coding RNA that has been identified as a potential drug target and biomarker. The analysis of the RNA-seq data and various experiments demonstrate that LINC01706 is associated with various cellular processes and is expressed at higher levels in cancer tissues compared to non-cancer samples. The potential role of LINC01706 as a drug target and biomarker makes it a promising target for cancer treatment and diagnosis. Further research is needed to fully understand the function of LINC01706 and its potential as a drug and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1706

The "LINC01706 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01706 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets